Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Mesa Biotech Gets FDA Clearance, CLIA Waiver for Flu A/B Test, POC System

Mesa Biotech Gets FDA Clearance, CLIA Waiver for Flu A/B Test, POC System

Feb 07, 2018

NEW YORK (GenomeWeb) – Mesa Biotech announced today it has received 510(k) clearance and CLIA waiver from the US Food and Drug Administration for a test to detect and distinguish influenza A and B from nasal swab specimens. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

What's Popular?

In PCR

  1. Facing 'Unfathomable' Demand, Quidel Ramps Up SARS-CoV-2 Test Production

    Premium

  2. Cleveland Clinic, Three Other Labs Get FDA EUAs for Coronavirus Tests

  3. SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency

    Premium

  4. NIH Awards $249M to Seven Firms for Rapid Acceleration of COVID-19 Diagnostics

  5. National Labs Focused on Building PCR SARS-CoV-2 Test Capacity in Anticipation of Fall

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.